Eloxx Pharmaceuticals closed at $12.80 on Nov 5, up 0.47%, 29.9% below its highest close since Apr 26. Volume of 34.9K shares was 1.37× its 20-day average (above normal).
Split-adjusted performance: -14.0% over one month.
Short interest was 41.3K shares at the Oct 15 settlement, down 23.3% from the prior report (1.3% of float, 1.8 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ELOXEloxx Pharmaceuticals | $12.80 | +0.47% | — | — | — | — | $51.7M | |
| INKTMiNK Therapeutics | $10.05 | −5.19% | −10.2% | — | — | — | $51.3M | Compare |
| GRMLGreenland Mines | $3.57 | −8.70% | — | — | — | — | $48.9M | Compare |
| KLRSKalaris Therapeutics | $2.36 | +16.83% | −54.2% | — | — | — | $56.2M | Compare |
| TILInstil Bio | $6.99 | 0.00% | −13.0% | — | — | — | $47.4M | Compare |
| IMAImageneBio | $4.17 | +1.59% | −29.5% | — | — | — | $47.3M | Compare |
| CRDFCardiff Oncology | $0.7553 | −13.07% | −52.8% | −14.0% | −8882.7% | — | $58.8M | Compare |
| CRBUCaribou Biosciences | $0.4123 | −7.22% | −78.1% | −43.8% | −1619.9% | — | $44.2M | Compare |
| CGTXCognition Therapeutics | $0.6354 | −7.01% | −45.2% | — | — | — | $60.4M | Compare |
No recent articles focused on Eloxx Pharmaceuticals.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
